tirzepatide and menopause New study links combination of hormone therapy to greater weight loss after Postmenopausal women on the GLP-1

ORourke JA, Graham MA (2021) Gene expression responses to sequential nutrient deficiency stresses in soybean

GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis

J., & Jaspers, I

Take 200-400 milligrams and expect results within 2-6 hours

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) is the landmark efficacy data: tirzepatide at 15mg weekly produced 22.5% average body weight reduction over 72 weeks in adults with obesity without diabetes the highest weight reduction ever documented in a pharmaceutical trial

Another limitation is that the pharmacokinetic assessments on the 10th day of dosing in the current trials do not fully reflect the steady-state situation achieved with continuous once-daily dosing in the clinical setting because of the long half-life of approximately 1 week for oral semaglutide